Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

High correlation between in vivo [123I]β-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats.

Bäck S, Raki M, Tuominen RK, Raasmaja A, Bergström K, Männistö PT.

EJNMMI Res. 2013 Jun 10;3(1):46. doi: 10.1186/2191-219X-3-46.

2.

Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT.

Scherfler C, Donnemiller E, Schocke M, Dierkes K, Decristoforo C, Oberladstätter M, Kolbitsch C, Zschiegner F, Riccabona G, Poewe W, Wenning G.

Neuroimage. 2002 Sep;17(1):128-41.

PMID:
12482072
3.

Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.

Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, Kim KM, Yoon KY, Lee MC, Lee SB.

Ann Neurol. 1998 Jun;43(6):792-800.

PMID:
9629849
4.

A novel use of combined tyrosine hydroxylase and silver nucleolar staining to determine the effects of a unilateral intrastriatal 6-hydroxydopamine lesion in the substantia nigra: a stereological study.

Healy-Stoffel M, Ahmad SO, Stanford JA, Levant B.

J Neurosci Methods. 2012 Sep 30;210(2):187-94. doi: 10.1016/j.jneumeth.2012.07.013. Epub 2012 Jul 28.

5.

Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.

Penttinen AM, Suleymanova I, Albert K, Anttila J, Voutilainen MH, Airavaara M.

J Neurosci Res. 2016 Apr;94(4):318-28. doi: 10.1002/jnr.23708. Epub 2016 Jan 13.

PMID:
26762168
6.

In vivo evaluation of the dopaminergic neurotransmission system using [123I]FP-CIT SPECT in 6-OHDA lesioned rats.

Niñerola-Baizán A, Rojas S, Bonastre M, Tudela R, Lomeña F, Pavía J, Marin C, Ros D.

Contrast Media Mol Imaging. 2015 Jan-Feb;10(1):67-73. doi: 10.1002/cmmi.1608. Epub 2014 May 28.

PMID:
24888455
7.

Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.

Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB.

J Nucl Med. 1998 Sep;39(9):1500-8.

8.

Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior.

Carman LS, Gage FH, Shults CW.

Brain Res. 1991 Jul 12;553(2):275-83.

PMID:
1681983
9.

Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.

Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC.

J Nucl Med. 1998 Jul;39(7):1143-8.

10.

Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.

Andringa G, Drukarch B, Bol JG, de Bruin K, Sorman K, Habraken JB, Booij J.

Neuroimage. 2005 Jul 15;26(4):1150-8.

PMID:
15908232
11.

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA.

J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):133-40.

12.

Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.

Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W.

Mov Disord. 2014 Dec;29(14):1767-73. doi: 10.1002/mds.25975. Epub 2014 Jul 22.

PMID:
25048738
13.

Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.

Greco A, Zannetti A, Pappatà S, Albanese A, Coda AR, Ragucci M, Nardelli A, Brunetti A, Cuocolo A, Salvatore M.

Q J Nucl Med Mol Imaging. 2015 Sep 1. [Epub ahead of print]

PMID:
26329495
14.

Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry.

Depboylu C, Maurer L, Matusch A, Hermanns G, Windolph A, Béhé M, Oertel WH, Höglinger GU.

Neuroimage. 2013 Oct 1;79:191-200. doi: 10.1016/j.neuroimage.2013.04.076. Epub 2013 Apr 28.

PMID:
23631981
15.

Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.

Molinet-Dronda F, Gago B, Quiroga-Varela A, Juri C, Collantes M, Delgado M, Prieto E, Ecay M, Iglesias E, Marín C, Peñuelas I, Obeso JA.

Neurobiol Dis. 2015 May;77:165-72. doi: 10.1016/j.nbd.2015.01.007. Epub 2015 Feb 12.

PMID:
25681534
16.

N-(3-Fluoropropyl)-2β-carbomethoxy-3β-(4-[123I]iodophenyl)nortropane.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2004 Dec 16 [updated 2011 Feb 1].

17.
18.

Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, Seibyl JP.

Mov Disord. 1999 May;14(3):436-42.

PMID:
10348466
20.

Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.

Jeon B, Kim JM, Jeong JM, Kim KM, Chang YS, Lee DS, Lee MC.

J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):60-4.

Supplemental Content

Support Center